 |
The following information is NOT intended to endorse drugs or recommend therapy. While these reviews might be helpful, they are not a substitute for the expertise, skill, knowledge and judgement of healthcare practitioners in patient care.
Learn more about Rebif.
No reviews have yet been submitted. Be the first to review this drug.
New research suggests that in addition to the disabling lesions it's known to cause, multiple sclerosis also damages the part of the brain that affects...
Paris, France – December 20, 2011 – Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme today reported top-line results from TENERE, a Phase...
From Associated Press (December 20, 2011) French drug maker Sanofi's Genzyme unit said its potential multiple sclerosis treatment teriflunomide showed no...
Once-daily oral MS medicine showed a 48% relative reduction in annualized relapse rate, meeting primary endpoint in Phase III placebo-controlled...
Dec 7, 2011 - Multiple sclerosis (MS) may progress from the outermost layers of the brain to its deep parts, and isn't always an “inside-out” process...
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines & natural products. This material is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Data sources include Micromedex™ (updated Jan 27th, 2011), Cerner Multum™ (updated Jan 3rd, 2012), Wolters Kluwer™ (updated Jan 31st, 2012) and others.
To view content sources and attributions, refer to our editorial policy.
Copyright © 2000-2012 Drugs.com. All rights reserved.
We comply with the HONcode standard for trustworthy health information.
Verify here
